Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access

Gavin Yamey,Shingai Machingaidze
DOI: https://doi.org/10.1136/bmj.q2254
2024-10-15
BMJ
Abstract:This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled trial found that twice yearly injection of the drug lenacapavir for pre-exposure prophylaxis (PrEP) was 100% effective at preventing HIV infection in cisgender women and was superior in efficacy to oral PrEP.2Then, on 12 September 2024, came an interim analysis of another randomised controlled trial , the Purpose-2 trial, conducted in Argentina, Brazil, Mexico, Peru, Thailand, and the United States (US), which enrolled cisgender and transgender men, transgender women, and gender non-binary individuals who have sex with partners assigned male at birth. In this second trial, lenacapavir for PrEP reduced the risk of HIV infection by 96% and was again superior in efficacy to oral PrEP.3Taken together, the World Health Organization said that the trials...
medicine, general & internal
What problem does this paper attempt to address?